NCT03442673 2025-03-28
MOCCCA
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
Clinical Trials
6 trialsNCT02506959 2025-03-18
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003401 2019-10-17
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
University of Maryland, Baltimore
Phase 2 Completed
NCT02791373 2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT00477035 2017-01-11
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Stanford University
Phase 1 Completed
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn